Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects

Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects

Abstract The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Science & public policy 2024-01, Vol.51 (1), p.144-148
Hauptverfasser: Nienow, Sara, Leonchuk, Olena, O’Connor, Alan C, Link, Albert N
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 148
container_issue 1
container_start_page 144
container_title Science & public policy
container_volume 51
creator Nienow, Sara
Leonchuk, Olena
O’Connor, Alan C
Link, Albert N
description Abstract The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute. This paper investigates the likelihood that a business funded through NHLBI’s Small Business Innovation Research (SBIR) program will commercialize from its Phase IIB translational support. Commercialization is one performance metric that quantifies a policy dimension of the success of the funded SBIR project. Based on an empirical analysis of sixty-one Phase IIB projects, we find that the most significant covariate with the likelihood of commercialization is the growth in human capital within the business since the Phase IIB award.
doi_str_mv 10.1093/scipol/scad063
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_scipol_scad063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/scipol/scad063</oup_id><sourcerecordid>10.1093/scipol/scad063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c228t-73c28d582533a28cf9a9b794534124ff8d72bc00980a581548a3bd267e48abfe3</originalsourceid><addsrcrecordid>eNqFkM1Kw0AUhQdRsFa3rmcrNHV-m4k7U6oNFBV_1uFmMklTYybMTBd9G5_FJzOS7oUL5y7OOXA-hK4pmVOS8Fuvm962g0BJFvwETaiIaSQFJ6doQjhhERcsPkcX3u8IIUwJOUGQuqarh8PB6G1nW1sfcLD4C9ynCXf4CUJjO2jx2oALM7zZd_UMQ1f-fKettSXOOh-asA8Gv6XZK37Zgjc4y1LcO7szOvhLdFZB683VUafo42H1vlxHm-fHbHm_iTRjKkQx10yVUjHJOTClqwSSIk6E5IIyUVWqjFmhCUkUAamoFAp4UbJFbIavqAyfovnYq5313pkq710zzDjklOR_gPIRUH4ENARuxoDd9_95fwEG9Wox</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Nienow, Sara ; Leonchuk, Olena ; O’Connor, Alan C ; Link, Albert N</creator><creatorcontrib>Nienow, Sara ; Leonchuk, Olena ; O’Connor, Alan C ; Link, Albert N</creatorcontrib><description>Abstract The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute. This paper investigates the likelihood that a business funded through NHLBI’s Small Business Innovation Research (SBIR) program will commercialize from its Phase IIB translational support. Commercialization is one performance metric that quantifies a policy dimension of the success of the funded SBIR project. Based on an empirical analysis of sixty-one Phase IIB projects, we find that the most significant covariate with the likelihood of commercialization is the growth in human capital within the business since the Phase IIB award.</description><identifier>ISSN: 0302-3427</identifier><identifier>EISSN: 1471-5430</identifier><identifier>DOI: 10.1093/scipol/scad063</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><ispartof>Science &amp; public policy, 2024-01, Vol.51 (1), p.144-148</ispartof><rights>The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c228t-73c28d582533a28cf9a9b794534124ff8d72bc00980a581548a3bd267e48abfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,1585,27929,27930</link.rule.ids></links><search><creatorcontrib>Nienow, Sara</creatorcontrib><creatorcontrib>Leonchuk, Olena</creatorcontrib><creatorcontrib>O’Connor, Alan C</creatorcontrib><creatorcontrib>Link, Albert N</creatorcontrib><title>Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects</title><title>Science &amp; public policy</title><description>Abstract The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute. This paper investigates the likelihood that a business funded through NHLBI’s Small Business Innovation Research (SBIR) program will commercialize from its Phase IIB translational support. Commercialization is one performance metric that quantifies a policy dimension of the success of the funded SBIR project. Based on an empirical analysis of sixty-one Phase IIB projects, we find that the most significant covariate with the likelihood of commercialization is the growth in human capital within the business since the Phase IIB award.</description><issn>0302-3427</issn><issn>1471-5430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkM1Kw0AUhQdRsFa3rmcrNHV-m4k7U6oNFBV_1uFmMklTYybMTBd9G5_FJzOS7oUL5y7OOXA-hK4pmVOS8Fuvm962g0BJFvwETaiIaSQFJ6doQjhhERcsPkcX3u8IIUwJOUGQuqarh8PB6G1nW1sfcLD4C9ynCXf4CUJjO2jx2oALM7zZd_UMQ1f-fKettSXOOh-asA8Gv6XZK37Zgjc4y1LcO7szOvhLdFZB683VUafo42H1vlxHm-fHbHm_iTRjKkQx10yVUjHJOTClqwSSIk6E5IIyUVWqjFmhCUkUAamoFAp4UbJFbIavqAyfovnYq5313pkq710zzDjklOR_gPIRUH4ENARuxoDd9_95fwEG9Wox</recordid><startdate>20240129</startdate><enddate>20240129</enddate><creator>Nienow, Sara</creator><creator>Leonchuk, Olena</creator><creator>O’Connor, Alan C</creator><creator>Link, Albert N</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20240129</creationdate><title>Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects</title><author>Nienow, Sara ; Leonchuk, Olena ; O’Connor, Alan C ; Link, Albert N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c228t-73c28d582533a28cf9a9b794534124ff8d72bc00980a581548a3bd267e48abfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nienow, Sara</creatorcontrib><creatorcontrib>Leonchuk, Olena</creatorcontrib><creatorcontrib>O’Connor, Alan C</creatorcontrib><creatorcontrib>Link, Albert N</creatorcontrib><collection>CrossRef</collection><jtitle>Science &amp; public policy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nienow, Sara</au><au>Leonchuk, Olena</au><au>O’Connor, Alan C</au><au>Link, Albert N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects</atitle><jtitle>Science &amp; public policy</jtitle><date>2024-01-29</date><risdate>2024</risdate><volume>51</volume><issue>1</issue><spage>144</spage><epage>148</epage><pages>144-148</pages><issn>0302-3427</issn><eissn>1471-5430</eissn><abstract>Abstract The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute. This paper investigates the likelihood that a business funded through NHLBI’s Small Business Innovation Research (SBIR) program will commercialize from its Phase IIB translational support. Commercialization is one performance metric that quantifies a policy dimension of the success of the funded SBIR project. Based on an empirical analysis of sixty-one Phase IIB projects, we find that the most significant covariate with the likelihood of commercialization is the growth in human capital within the business since the Phase IIB award.</abstract><cop>UK</cop><pub>Oxford University Press</pub><doi>10.1093/scipol/scad063</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-3427
ispartof Science & public policy, 2024-01, Vol.51 (1), p.144-148
issn 0302-3427
1471-5430
language eng
recordid cdi_crossref_primary_10_1093_scipol_scad063
source Oxford University Press Journals All Titles (1996-Current)
title Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T23%3A48%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bringing%20technology%20to%20market:%20National%20Heart,%20Lung,%20and%C2%A0Blood%20Institute%20SBIR%20Phase%20IIB%20projects&rft.jtitle=Science%20&%20public%20policy&rft.au=Nienow,%20Sara&rft.date=2024-01-29&rft.volume=51&rft.issue=1&rft.spage=144&rft.epage=148&rft.pages=144-148&rft.issn=0302-3427&rft.eissn=1471-5430&rft_id=info:doi/10.1093/scipol/scad063&rft_dat=%3Coup_cross%3E10.1093/scipol/scad063%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/scipol/scad063&rfr_iscdi=true